AARTIPHARM Aarti Pharmalabs Q2 FY27 results (Jul–Sep 2026) and concall
Aarti Pharmalabs had a record Q2 FY27. Standalone revenue rose 47% YoY to ₹613 crores and EBITDA rose 84% to ₹136 crores at a 22.2% margin. Growth was broad: Xanthine & allied chemistry held at about a ₹1,200 crore annualized run-rate, the API business recovered after the steroid block debottlenecking, and CDMO revenue nearly doubled QoQ. Management reiterated 40-50% CDMO growth for FY27 and a long-term CDMO target of ₹1,000 crores ($100 million). It declined to upgrade its 3-year guidance. The main things to watch are rising working capital, rising debt, high raw material costs and higher dep
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 611.1%, net profit up 153.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 20 | 11 | -30 | -9 | -20 −200% | 3 −73% | 39 +230% | 46 +611% |
| EBITDA | 129 | 146 | 93 | 74 | 102 −21% | 113 −23% | 136 +46% | 135 +82% |
| Net profit | 74 | 88 | 50 | 28 | 48 −35% | 61 −31% | 76 +52% | 71 +154% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
